Literature DB >> 16381997

Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism.

Keisuke Kobayashi1, Yasuo Imanishi, Akimitsu Miyauchi, Naoyoshi Onoda, Takehisa Kawata, Hideki Tahara, Hitoshi Goto, Takami Miki, Eiji Ishimura, Toshitsugu Sugimoto, Tetsuro Ishikawa, Masaaki Inaba, Yoshiki Nishizawa.   

Abstract

OBJECTIVE: While the importance of fibroblast growth factor (FGF)-23 is established in phosphate-wasting disorders, little is known about the mechanisms regulating its circulating level. To investigate the role of parathyroid hormone (PTH) and calcium in FGF-23 metabolism, we examined plasma FGF-23 levels in patients with primary hyperparathyroidism (PHPT). PATIENTS AND METHODS: Fifty patients with PHPT and 52 controls were employed in this study. Plasma was obtained from 18 PHPT patients who underwent parathyroidectomy (PTX) on the first postoperative morning without vitamin D administration. Time-course samples were also obtained from 5 of 18 PTX patients without vitamin D analogs or calcium administration. The expression of Fgf23 on resected parathyroid glands was analyzed by reverse transcription (RT)-PCR and immunohistochemistry.
RESULTS: FGF-23 was significantly elevated in PHPT patients compared with controls. FGF-23 levels were significantly correlated positively with serum corrected calcium and intact PTH levels, and negatively with creatinine clearance and inorganic phosphate, among which creatinine clearance and corrected calcium were independently associated factors. In 18 PTX patients, postoperative FGF-23 levels were significantly decreased compared with preoperative levels. Corrected-calcium levels were significantly decreased 1 h after PTX, and this was followed by a reduction in plasma FGF-23 levels in time-course study. In addition, postoperative FGF-23 levels in 18 PTX patients were significantly correlated with corrected calcium, consistent with a role of serum calcium as one of the major regulators of FGF-23. The absence of Fgf23 expression in parathyroid glands indicated that the parathyroid glands were not major sources of circulating FGF-23.
CONCLUSIONS: Serum calcium may regulate circulating FGF-23 levels in PHPT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16381997     DOI: 10.1530/eje.1.02053

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  41 in total

1.  Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.

Authors:  Justine Bacchetta; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

2.  Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.

Authors:  Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 8.237

Review 3.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

4.  Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.

Authors:  Xiuqin Zhang; Omar A Ibrahimi; Shaun K Olsen; Hisashi Umemori; Moosa Mohammadi; David M Ornitz
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

5.  Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men.

Authors:  Sherri-Ann M Burnett-Bowie; Natalia Mendoza; Benjamin Z Leder
Journal:  Bone       Date:  2006-12-08       Impact factor: 4.398

Review 6.  Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Exp Cell Res       Date:  2012-03-07       Impact factor: 3.905

7.  Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia.

Authors:  Whitney W Brown; Harald Jüppner; Craig B Langman; Heather Price; Emily G Farrow; Kenneth E White; Kenneth L McCormick
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

8.  Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Authors:  Rodrigo B Oliveira; Ana L E Cancela; Fabiana G Graciolli; Luciene M Dos Reis; Sérgio A Draibe; Lilian Cuppari; Aluizio B Carvalho; Vanda Jorgetti; Maria E Canziani; Rosa M A Moysés
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-12       Impact factor: 8.237

9.  Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry.

Authors:  Dominique Kosk; Holly Kramer; Amy Luke; Pauline Camacho; Pascal Bovet; Jacob Plange Rhule; Terrence Forrester; Myles Wolf; Chris Sempos; Michal L Melamed; Lara R Dugas; Richard Cooper; Ramon Durazo-Arvizu
Journal:  J Bone Miner Metab       Date:  2016-12-09       Impact factor: 2.626

10.  Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial.

Authors:  S M Bristow; G D Gamble; A Pasch; W C O'Neill; A Stewart; A M Horne; I R Reid
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.